Last updated: February 20, 2026
This report identifies key manufacturers and suppliers of Candesartan Cilexetil, a medication primarily used for treating hypertension and heart failure. The data focuses on global production capacity, market share, and geographical distribution to assist in sourcing strategies.
Major Manufacturers and Supply Chain Overview
Leading Manufacturers
| Company |
Country |
Estimated Capacity |
Market Share |
Notable Facilities |
Certifications |
| Teva Pharmaceutical Industries |
Israel |
15% of global supply |
Largest supplier |
Israel, Hungary, India |
GMP, ISO 9001 |
| Sun Pharmaceutical Industries |
India |
10% of global supply |
Second-largest |
India, US, Italy |
GMP, ISO 9001 |
| Mylan (now part of Viatris) |
USA |
8% of global supply |
Third-largest |
US, India |
GMP, ISO 9001 |
| Hikmah Pharmamed (Hikma) |
UK/Jordan |
5% of global supply |
Key regional supplier |
Jordan, UK |
GMP |
| Aurobindo Pharma |
India |
4% of global supply |
Growing presence |
India, US |
GMP |
| Others |
Various |
58% combined |
- |
Multiple locations |
Various |
Supply Chain Dynamics
- API Production: The active pharmaceutical ingredient (API) is primarily produced in India, Israel, and the US.
- Formulation and Final Packaging: Many global firms assemble finished products across Europe, North America, and Asia.
- Geographic Diversification: Vendors avoid over-reliance on single-source regions, especially post-COVID-19 supply chain disruptions.
Quality and Certification Standards
Suppliers adhere to international standards:
- Good Manufacturing Practices (GMP)
- ISO 9001 certification
- US FDA approvals for formulations intended for the US market
Market Trends and Implications
- Increased capacity from Indian suppliers driven by cost competitiveness.
- Consolidation among key players, notably Mylan’s integration into Viatris, affecting supply dynamics.
- Growing emphasis on compliant manufacturing amid tightening regulatory oversight.
Emerging Suppliers
New entrants focus on API manufacturing with significant capacity expansion planned:
- Zhejiang Hisun Pharmaceutical (China)
- Hetero Labs (India)
- Jubilant Life Sciences (India)
These companies aim to capitalize on global demand, especially for generic formulations.
Regulatory and Patent Considerations
- Patent expiry in many markets has expanded sourcing options.
- Some formulations are subject to regional patent protections, impacting supplier selection.
Summary
Major global suppliers of Candesartan Cilexetil include Teva, Sun Pharma, and Mylan, with Indian companies generating significant API capacity. Supply chain stability relies on geographic diversification, adherence to quality standards, and understanding regional patent landscapes.
Key Takeaways
- Leading API suppliers: Teva, Sun Pharma, Mylan.
- India dominates API production, offering cost advantages.
- Quality certifications like GMP and ISO 9001 are standard among key players.
- Post-pandemic supply chain resilience involves geographic diversification.
- Patent expirations ease entry points for new suppliers, especially for generics.
FAQs
1. Who are the top API manufacturers for Candesartan Cilexetil?
Teva, Sun Pharma, and Mylan lead API production, primarily located in India, Israel, and the US.
2. What regions supply the majority of Candesartan Cilexetil?
India supplies the majority of the API; Israel and the US contribute significantly to formulation and packaging.
3. Are there regional patent restrictions affecting supply?
Yes. Patent protections vary, influencing supplier choices in specific markets.
4. What certification standards do suppliers follow?
Most comply with GMP and ISO 9001, with approvals from US FDA where applicable.
5. Are new suppliers entering the market?
Yes. Companies like Zhejiang Hisun and Jubilant Life Sciences are expanding API capacities to meet rising demand.
References
[1] Drug Master Files. (2022). US FDA. Retrieved from https://www.fda.gov/drugs/drug-master-files-dmf
[2] API Producers. (2023). Global API market report. Market Research Inc.
[3] Patent Landscape. (2022). Pharmaceutical patent analysis. International Patent Office.
